RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($) |
1 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Apr. 11, 2024 |
Jan. 31, 2022 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Apr. 12, 2024 |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
| Debt funded to Marizyme | $ 4,166,900 | |||||
| License Agreement [Member] | ||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
| Reimbursement of patent | $ 160,000 | |||||
| License cost | $ 0 | $ 0 | ||||
| Co Development Agreement [Member] | ||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
| Marizyme agreement terms | which has subsequently been amended. Under the terms of the Co-Development Agreement, the Company committed to provide funding payments to Marizyme and pay a one-time exclusivity fee of $200,000. The $200,000 exclusivity fee and an initial $500,000 funding payment were remitted to Marizyme on April 12, 2024, and both amounts were recorded within research and development expenses on the unaudited condensed consolidated statements of operations and other comprehensive loss in the respective periods of payment. The exclusivity fee granted the Company an exclusive negotiating window through May 31, 2024 to negotiate a comprehensive strategic partnership covering Marizyme’s DuraGraft product line. The funding payments proceeds were intended to financially support the commercial rollout of Marizyme’s DuraGraft™ vascular conduit system, a device indicated for adult patients receiving coronary artery bypass graft surgery, used for flushing and preserving saphenous vein grafts for such procedures. In exchange for the funding contributions, the Company is entitled to quarterly revenue-based payments analogous to royalties equal to 33% of DuraGraft Net Sales (Net Sales defined consistently with gross profit derived from net product sales). The aggregate maximum amount of these royalty-like payments is capped at twice the total funding advanced by the Company. No royalty-like obligations accrue to Marizyme, and no payments to the Company are required, until two thresholds are satisfied: DuraGraft achieves commercial launch in the United States, and cumulative U.S. Net Sales of DuraGraft reach $500,000. | |||||
| Exclusivity Fee | $ 200,000 | |||||
| Debt funded to Marizyme | $ 500,000 | |||||
| Upfront Payment [Member] | License Agreement [Member] | ||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||||
| Reimbursement of patent | $ 150,000 | |||||